The intradermal vaccination: Past experiences and current perspectives

Journal of Preventive Medicine and Hygiene

Volumn 51, Issue 1, 2010, Pages 7-14

  Sticchi, L ^a,b   Alberti, Marisa ^a   Alicino, C ^a   Crovari, P ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Immune response; Influenza vaccine; Intradermal vaccination

Indexed keywords

BCG VACCINE; HEMAGGLUTININ; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; INTANZA; MEASLES VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; TUBERCULIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG SAFETY; HEPATITIS A; HEPATITIS B; HUMAN; INFLUENZA; INNATE IMMUNITY; INTRADERMAL DRUG ADMINISTRATION; LOW DRUG DOSE; MEASLES; MEASLES VACCINATION; POLIOMYELITIS; RABIES; REVIEW; VACCINATION; ANTIBODY PRODUCTION; DEVICES; DRUG DELIVERY SYSTEM; IMMUNOLOGY; MICROINJECTION; PROCEDURES;

ANTIBODY FORMATION; DRUG DELIVERY SYSTEMS; HEPATITIS B VACCINES; HUMANS; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; MICROINJECTIONS; VACCINATION;

EID: 77954376904     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Spellberg B. The cutaneous citadel: a holistic view of skin and immunity. Life Sci 2000;67:477-502.
2. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008;26:3197-208.
3. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008;7:1201-14.
4. Le Borgne M, Etchart N, Goubier A, et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell cross priming in vivo. Immunity 2006;24:191-201.
5. Allan RS, Waithman J, Bedoui S, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006;25:153-62.
6. Itano AA, Jenkins MK. Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol 2003;4:733-9.
7. Plotkin SA. Vaccines: the fourth century. Clin Vaccine Immunol 2009;16:1709-19.
8. Mantoux C. L'intradermoréaction a la tuberculine et son interprétation clinique. Presse Medicale 1910;18:10-3.
9. Bricks LF. Percutaneous or intradermal BCG vaccine? J Pediatria 2004;80:93-8.
10. Briggs DJ, Banzhoff A, Nicolay U, et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull WHO 2000;78:693-8.
11. Tuft L. Active immunization against thyphoid fever, with particular reference to an intradermal method. J Lab Clin Med 1931;16:552-6.
12. Cutts FT, Clemants CJ, Bennett JV. Alternative route of measles immunization: a review. Biologicals 1997;25:323-38.
13. Nicholson KG, Prestage H, Cole PJ, et al. Multsite intradermal antirabies vaccination. Immune response in man and protection of rabbits against death from street virus by postexposure administration of human diploid-cell-strain rabies vaccine. Lancet 1981;2:915-8.
14. Warrell MJ, Nicholson KG, Warrell DA, et al. Economical multiple-site intradermal immunization with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1985;1:1059-62.
15. Connolly JH, Dirk GW, Corkin DL. Antibody response following intradermal or oral administration of formalinised poliomyelitis. Lancet 1958;2:333-6.
16. Nirmal S, Cherian T, Samuel BU, et al. Immune response of infants to fractional doses of intradermally administrated inactivated poliovirus vaccine. Vaccine 1998;16:928-31.
17. Frösner G, Steffen R, Herzog C. Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration. J Travel Med 2009;16:413-9.
18. Miller KD, Gibbs RD, Mulligan NM, et al. Intradermal hepatitis B virus vaccine: immunogenicity and side effects in adults. Lancet 1983;2:1454-6.
19. Clarke JA, Hollinger FB, Lewis E, et al. Intradermal inoculation with Heptavax-B immune response and histologic evaluation of injection sites. JAMA 1989;26:2567-71.
20. Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009;27:7304-12.
21. Leroux-Roels I, Vets E, Freese R, et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine 2008;26:6614-9.
22. Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008;198:650-8.
23. Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004;351:2295-301.
24. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009;27:454-9.
25. European Medicines Agency (EMA). Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. Available at http://www.emea.europa. eu/humandocs/PDFs/EPAR/intanza/H-957-en6.pdf - Accessed 10 February 2010.
26. Whittle HC, Rowland MG, Mann GF, et al. Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine. Lancet 1984;2:834-7.
27. Kok PW, Kenya PR, Ensering H. Measles immunization with further attenuated heat-stable measles vaccine using five different methods of administration. Trans R Soc Trop Med Hyg 1983;77:171-6.
28. Burland WL. Measles vaccination by the intradermal route. Postgrad Med J 1969;45:323-6.
29. Fishbein DB, Pacer RE, Holmes DF, et al. Rabies pre-exposure prophylaxis with human diploid cell rabies vaccine: a dose-response study. J Infect Dis 1987;156:50-5.
30. Bernard KW, Roberts MA, Sumner J, et al. Human diploid cell rabies vaccine. Effectiveness of immunization with small intradermal or subcutaneous doses. JAMA 1982;247:1138-42.
31. Bernard KW, Mallonee J, Wright JC, et al. Preexposure immunization with intradermal human diploid cell rabies vaccine. Risks and benefits of primary and booster vaccination. JAMA 1987;257:1059-63.
32. World Health Organization (WHO). Rabies vaccines. WHO position paper. Wkly Epidemiol Rec 2007;82:425-35.
33. Samuel BU, Cherian T, Sridharan G, et al. Immune response to intradermally injected inactivated poliovirus vaccine. Lancet 1991;338:343-4.
34. Samuel BU, Cherian T, Rajasingh J, et al. Immune response of infants to inactivated poliovirus vaccine injected intradermally. Vaccine 1992;10:135.
35. Nirmal S, Cherian T, Samuel BU, et al. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998;16:928-31.
36. Eighth WHO/Unicef consultation with opv/ipv manufacturers and nras. 30 October 2009, Geneva, who/hq. Available at: www.who.int/entity/immunization- standards/vaccine-quality/ ipvopv-summary3dec09.pdf. Accessed February 7, 2010.
37. Brindle RJ, Morris CA, Berger R, et al. Inadequate response to intradermal hepatitis A vaccine. Vaccine 1994;12:483-4.
38. Carlsson U, Brudin L, Eliasson I, et al. Hepatitis A vaccination by intracutaneous low dose administration: a less expensive alternative. Scand J Infect Dis 1996;28:435-8.
39. Pancharoen C, Mekmullica J, Thisyakorn U, et al. Reduced-dose intradermal vaccination against hepatitis A with an aluminum- free vaccine is immunogenic and can lower costs. Clin Infect Dis 2005;41:1537-40.
40. Chen W, Gluud C. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database Syst Rev 2005;(4): CD000100.
41. Sangaré L, Manhart L, Zehrung D, e al. Intradermal hepatitis B vaccination: a systematic review and meta-analysis. Vaccine 2009;27:1777-86.
42. Heijtink RA, Knol RM, Schalm SW. Low-dose (2 micrograms) hepatitis B vaccination in medical students: comparable immunogenicity for intramuscular and intradermal routes. J Med Virol 1989;27:151-4.
43. Rahman F, Dahmen A, Herzog-Hauff S, et al. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000;31:521-7.
44. Milne A, Allwood GK, Pearce NE, et al. Low dose hepatitis B vaccination in children. N Z Med J 1986;99:47-9.
45. Ayoola EA. Hepatitis B vaccine in developing countries: problems and prospects. IARC Sci Publ 1984;(63):297-305.
46. Coberly JS, Townsend T, Repke J, et al. Suboptimal response following intradermal hepatitis B vaccine in infants. Vaccine 1994;12:984-7.
47. Wahl M, Hermodsson S. Intradermal, subcutaneous or intramuscular administration of hepatitis B vaccine: side effects and antibody response. Scand J Infect Dis 1987;19:617-21.
48. Micozkadioglu H, Zumrutdal A, Torun D, et al. Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients. Ren Fail 2007;29:285-8.
49. Shafran SD, Mashinter LD, Lindemulder A, et al. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine. HIV Med 2007;8:295-9.
50. Ristola MA, Vuola JM, Valle M, et al. Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects. Vaccine 2004;23:205-9.
51. Weller TH, Cheever FS, Enders JF. Immunologic reactions following the intradermal inoculation of influenza A and B vaccine. Proc Soc Exp Biol Med 1948;67:96-101.
52. Boger WP, Liu OC. Subcutaneous and intradermal vaccination with Asian influenza vaccine. JAMA 1957;165:1687-9.
53. McCarroll JR, Kilbourne ED. Immunization with Asian-strain influenza vaccine. New Engl J Med 1958;259:618-21.
54. Brown H, Kasel JA, Freeman DM, et al. The immunizing effect of influenza A/NewJersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J Infect Dis 1977;136:(Suppl):S466-S471.
55. Halperin W, Weiss WI, Altman R, et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. Am J Public Health 1979;69:1247-5.
56. European Medicines Agency (EMA). Committee for proprietary medicinal products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. Available at: http://www.ema.europa.eu/pdfs/human/bwp/ 021496en.pdf Accessed on 7 February 2010
57. Jo YM, Song JY, Hwang IS, et al. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. J Med Virol 2009;81:722-7.
58. Chiu SS, Peiris JS, Chan KH, et al. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 2007;119:1076-82.
59. Chiu SS, Chan KH, Tu W, et al. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial. Vaccine 2009;27:4834-9.
60. Belshe RB, Newman FK, Wilkins K, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007;25:6755-63.
61. Beran J, Ambrozaitis A, Laiskonis A, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009;7:13.
62. Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004;351:2295-301.
63. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351:2286-94.
64. Auewarakul P, Kositanont U, Sornsathapornkul P, et al. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007;25:659-63.
65. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004;103:133-8.
66. Vu T, Farish S, Jenkins M, et al. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002;20:1831-6.
67. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010;10:639-51.
68. Van Damme P. Evaluation of non-inferiority of intradermal versus adjuvanted influenza vaccine with two serological techniques. Poster PB7 513 presented at IAGG World Congress - Paris, 5-9 July 2009.
69. European Medicines Agency (EMA). EPARs for authorized medicinal products for human use. Available at: http://www. ema.europa.eu/humandocs/Humans/EPAR/ intanza/intanza.htm Accessed on 10 February 2010
70. Kravitz H. A simplified technique for vaccination against small pox. Pediatrics 1961;27:219-26.
71. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006;58:68-89.
72. PATH. Shots without needles. A safer, cheaper way to get vaccines where they are needed most. Available at: http://www. path.org/projects/jet-injector. php Accessed February 7, 2010.
73. WHO (World Health Organization). Intradermal Delivery of Vaccines. A review of the literature and the potential for development for use in low- and middle-income countries. August 27, 2009.
74. Laurent PE, Bonnet S, Alchas P, Regolini, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007;25:8833-42.